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SUMMARY
Acute myeloid leukemia (AML) manifests as phenotypically and functionally diverse cells, often 
within the same patient. Intratumor phenotypic and functional heterogeneity have been linked 
primarily by physical sorting experiments, which assume that functionally distinct subpopulations 
can be prospectively isolated by surface phenotypes. This assumption has proven problematic and 
we therefore developed a data-driven approach. Using mass cytometry, we profiled surface and 
intracellular signaling proteins simultaneously in millions of healthy and leukemic cells. We 
developed PhenoGraph, which algorithmically defines phenotypes in high-dimensional single-cell 
data. PhenoGraph revealed that the surface phenotypes of leukemic blasts do not necessarily 
reflect their intracellular state. Using hematopoietic progenitors, we defined a signaling-based 
measure of cellular phenotype, which led to isolation of a gene expression signature that was 
predictive of survival in independent cohorts. This study presents new methods for large-scale 
analysis of single-cell heterogeneity and demonstrates their utility, yielding insights into AML 
pathophysiology.
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Intratumor heterogeneity is accepted to be functionally and clinically significant (Marusyk et 
al., 2012). Recent evidence implies that the pathobiology of cancer results from the actions 
and interactions of diverse subpopulations within the tumor. Thus, it is necessary to study 
tumors with methods that preserve single-cell resolution. Emerging technologies such as 
mass cytometry (Bendall et al., 2011) and single-cell RNAseq (Patel et al., 2014) have 
attained dramatic increases in dimensionality and throughput, bringing unprecedented 
resolution to the diversity of cellular states detectable in a given tissue. Yet, to take 
advantage of these technological gains, computational methods are required to robustly 
identify high-dimensional phenotypes and compare them within and between individuals. 
Data-driven phenotypic dissection may then form the basis for downstream analyses in 
which subpopulations are isolated and compared, revealing the role of complex population 
structure in uncharacterized systems such as malignancies.
Intratumor heterogeneity is pervasive in acute myeloid leukemia (AML), an aggressive 
liquid tumor of the bone marrow characterized by an overwhelming abundance of poorly 
differentiated myeloid cells (‘blasts’). Arising from the disruption of regulated myeloid 
differentiation (Tenen, 2003), AML results in a disordered developmental hierarchy wherein 
leukemic stem cells (LSCs) are capable of re-establishing the disease in immunodeficient 
mice (Bonnet and Dick, 1997). LSCs were first thought to be restricted to the same CD34+/
CD38− cellular compartment as normal hematopoietic stem cells (HSCs). Subsequent 
studies have demonstrated increased plasticity in AML where both CD38+ (Taussig et al., 
2008) and CD34− (Taussig et al., 2010) cells have LSC capacity, indicating that AML does 
not follow the hierarchy of normal hematopoiesis. While AML exhibits a differentiated 
hierarchy, no uniform phenotypic identifier for LSCs has been found across patients (Eppert 
et al., 2011).
Recognizing a disconnect between functionally primitive (e.g., tumor-initiating) cells 
associated with cancer persistence and their surface phenotype, we simultaneously examined 
surface antigen expression and regulatory signaling in individual AML cells. We reasoned 
that intracellular signaling rather than antigen profile more accurately represents the 
functional state of a diseased cell. We used mass cytometry to measure protein expression 
and activation state in millions of cells from AML patients and healthy bone marrow donors 
in 31 simultaneous dimensions. By measuring cells after ex vivo perturbations we further 
expanded the dimensionality of the data by revealing functional responses to environmental 
cues reflecting the broader cellular network beyond what can be inferred from the 
unperturbed state (Irish et al., 2004). To avoid the pitfalls of manual gating, we developed 
PhenoGraph, a robust computational method that partitions high-dimensional single-cell 
data into subpopulations. Building on these subpopulations we developed additional 
methods to extract high-dimensional signaling phenotypes and infer differences in 
functional potential between subpopulations.
Our data-driven approach revealed two new perspectives on the pathobiology of AML. First, 
we found that pediatric AML draws from a surprisingly limited repertoire of surface 
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phenotypes, indicating some memory of normal myelopoiesis. Despite genetic diversity, 
patterns of surface antigen expression followed trends in myeloid development, indicating 
limits in the ability of leukemic cells to phenotypically diverge from normal antigen profiles. 
Second, we found that the signaling pattern of undifferentiated hematopoietic progenitors 
defined a primitive signaling phenotype that was recapitulated in a majority of AML 
samples at varying frequencies. Functionally primitive leukemic cells—defined by signaling
—were not linked to a consistent surface phenotype, including the standard HSC/LSC 
antigen profile (i.e., CD34+/CD38−), demonstrating that surface antigens are decoupled from 
regulatory networks in leukemia. The frequency of these functionally primitive cells enabled 
isolation of a gene expression signature that was enriched for stem cell annotations and 
formed a significant predictor of overall survival in independent AML clinical cohorts.
Taken together, we provide an alternative paradigm for identifying primitive cancer cells 
that complements the immunophenotypic definitions of cancer stem cells traditionally used 
in both AML and other systems. Moreover, this analysis framework is robust and broadly 
applicable to the characterization of subpopulation structure and function from single-cell 
data in a wide range of systems.
RESULTS
High-dimensional single-cell profiling of pediatric AML by mass cytometry
We used mass cytometry to obtain single-cell proteomic profiles of cryopreserved bone 
marrow aspirates from pediatric AML patients obtained at diagnosis (n = 16) and from 
healthy adult donors (n = 5). We performed preliminary analysis to select 16 highly 
informative surface markers that efficiently captured the intra- and intertumor heterogeneity 
in our cohort (see Extended Experimental Procedures). We added 14 antibody probes 
against intracellular phosphorylation, thus allowing simultaneous measurement of surface 
phenotype and signaling behavior in single cells. Each sample was subjected ex vivo to a 
battery of short-term molecular perturbations (cytokines and chemical inhibitors; Table S1) 
to elicit functionally relevant signaling responses (Bendall et al., 2011; Irish et al., 2004). 
The complete data set contained over 15 million single cells from 21 individuals measured 
in 31 simultaneous protein epitope dimensions following exposure to one of 18 conditions 
(Fig. 1A).
PhenoGraph dissects population structure in high-dimensional single-cell data
Complex tissues such as bone marrow are composed of biologically meaningful 
subpopulations that are phenotypically coherent despite the intrinsic variability that makes 
each cell unique. A fundamental challenge is to establish the major phenotypes present, 
enabling an efficient and meaningful profile of the tissue. While normal immune cells are 
typically binned into predefined “landmark” cell subsets, this strategy is unsuitable for less 
predictable or under-studied tissues such as cancer, where new phenotypes have been shown 
to occur. Thus a data-driven, unsupervised approach is needed that takes single-cell 
measurements and returns a grouping of cells into distinct subpopulations (i.e., clusters).
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Dimensionality reduction techniques such as stochastic neighbor embedding (SNE) (Amir et 
al., 2013; Maaten and Hinton, 2008) help visualize the data, but do not explicitly identify 
and partition cells into subpopulations. Moreover, not all subpopulations are visually distinct 
when rendering high-dimensional data in only two dimensions. We evaluated a number of 
leading methods for clustering fluorescence cytometry data and found that these did not 
perform well for mass cytometry data (Aghaeepour et al., 2013). Parametric methods (Pyne 
et al., 2009) require strong assumptions about the high-dimensional shape of cellular 
populations (e.g., ellipsoid, convex), which are violated in single-cell data (Amir et al., 
2013). Therefore a non-parametric approach is needed, yet these currently use unstable 
heuristics or suffer from computational inefficiency and do not scale well to higher 
dimensions. We found that as the number of dimensions increased, available methods 
routinely failed to correctly identify known subsets, gave inconsistent results and were 
prohibitively slow (see Extended Experimental Procedures).
To robustly discover subpopulations in high-dimensional single-cell data we developed 
PhenoGraph. The parameters measured for each cell define a point in high-dimensional 
space wherein clustering is tantamount to finding dense regions in this space. The difficulty 
is that density detection in high dimensions is both computationally hard and statistically 
unstable. Following our previous work (Bendall et al., 2014), we model this high-
dimensional space using a nearest-neighbor graph. In this graph, each cell is represented by 
a node and connected by a set of edges to a neighborhood of its most similar cells. The 
graph distills the high-dimensional distribution of single cells into a compact, information-
rich data structure that captures phenotypic relatedness and overcomes many of the pitfalls 
of standard geometries.
After the nearest-neighbor graph is constructed, the problem of density detection 
corresponds to the task of finding sets of highly interconnected nodes (Fig. 1B). To this end 
we borrow from the social network field, which has developed powerful algorithms to 
partition large social networks into communities (Girvan and Newman, 2002). In our setting, 
communities represent an accumulation of phenotypically similar cells that likely reflects 
biologically meaningful phenotypic stability, thus revealing stable cellular states in the 
population. Partitioning the graph into these communities produces a dissection of the 
population into phenotypically coherent subpopulations. Community detection algorithms 
make no assumption about the size, number, or form of subpopulations (Fortunato, 2010). 
Importantly, communities need not be convex, symmetric, or ellipsoid—assumptions that 
are questionable for complex cellular populations. Efficient implementations can partition 
large graphs in minimal computation time (Blondel et al., 2008).
A key step in the PhenoGraph method is converting the single-cell data to a graph that 
faithfully represents the phenotypic relationships between cells. Without a carefully 
constructed graph, large populations can obscure rare ones (which may be outnumbered by 
orders of magnitude). This problem is further exacerbated by measurement noise that can 
spuriously link unrelated parts of the graph. We addressed both problems by constructing 
the graph in two iterations, using the Jaccard similarity coefficient in the second iteration. 
Thus, the similarity between cells is redefined by the number of shared neighbors following 
the first iteration (see Experimental Procedures and Fig. S1). The Jaccard metric exploits the 
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local density at each data point, removing spurious edges and strengthening well-supported 
ones. The co-occurrence of rare cells in the same phenotypic vicinity produces strongly 
interconnected modules that distinguish these rare cells from noise. Overall, the modular 
nature of the population is better revealed in the resulting graph.
Healthy human bone marrow, which is rich in distinct and well-characterized 
immunological cell types, presents a benchmark case for phenotypic dissection. We tested 
PhenoGraph on three different mass cytometry data sets of healthy human bone marrow 
(Bendall et al., 2011) and PhenoGraph correctly identified labeled immune cell types, 
displaying superior precision, recall and robustness against leading methods (Aghaeepour et 
al., 2013) (see Extended Experimental Procedures and Figs. 2, S2A–C & Data S1). 
PhenoGraph runs efficiently on large data sets with substantially better scaling than other 
methods (Fig. S2D) and can process millions of cells with modest computational resources. 
PhenoGraph is able to resolve subpopulations as rare as 1/2000 cells, and is robust to 
random subsampling and to the choice of the single user-defined parameter (Figs. 2, S2A–C 
& Data S1).
Conformity of phenotypes in the landscape of AML
After validating PhenoGraph on healthy cells, we applied it to our pediatric AML cohort. 
We ran PhenoGraph on each sample individually, defining subpopulations based on the 16 
measured surface markers. This yielded an average of 28 subpopulations per sample 
(ranging between 17 and 48), totaling 616 subpopulations across the entire cohort. 
Subpopulation size varied by orders of magnitude, from 7×102 to 2×105 cells (or .06% to 
20% of a sample). For each sample, we pooled data from all conditions, enabling 
characterization of subpopulation-specific signaling patterns. Each resulting subpopulation 
was a multifaceted data object, containing information about surface phenotypes, as well as 
the response of each signaling marker to each molecular perturbation (Fig. 1C).
Each leukemia presented a diversity of surface phenotypes defined by distinct combinations 
of marker expression (Data S2A). We sought an overview of the similarities and differences 
between detected subpopulations across patients that could reveal larger trends and enable 
direct comparison of all subpopulations simultaneously. To do so, we began by representing 
each PhenoGraph subpopulation by its surface marker centroid. We then used t-SNE 
(Maaten and Hinton, 2008), to reduce the 16-dimensional data to 2 dimensions, following an 
approach previously taken with cytometry data (Amir et al., 2013). The resulting 2D 
landscape provided an intuitive and comprehensive overview of the major phenotypes 
present in the cohort and also demonstrated the extent of intra- and inter-tumoral 
heterogeneity or similarity (Fig. 3A). Subpopulations from healthy and leukemic samples 
were mapped simultaneously so the healthy cell types could act as “landmarks” to aid 
interpretation of the leukemic subpopulations. Normal lymphoid cell types were excluded 
from the landscape (see Extended Experimental Procedures) to focus on primitive and 
myeloid phenotypes, “zooming in” on the myeloid lineages relevant to AML.
The AML cohort landscape organized the subpopulations into regions of phenotypic 
similarity, distinguished by particular marker combinations. Inspecting the structure of this 
landscape, we found that the vertical axis largely mimicked trends in normal myeloid 
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development with primitive markers expressed toward the top and more mature markers 
toward the bottom (Fig. 3A & Data S2B–C). Healthy CD34+/CD38mid hematopoietic stem 
and progenitor cells (HSPCs) provided the most primitive landmark, located at the top of the 
landscape plot. AML subpopulations in this region displayed surface profiles that resembled 
the HSPC phenotype. At the bottom of the landscape, the CD11b+ healthy monocytes served 
as a landmark for differentiated myeloid cells, representing full maturation not observed in 
the leukemic samples. Between these two poles, other developing myeloid antigens—CD38, 
CD117, CD123, CD33—peaked and subsided, thus the vertical axis of the landscape 
resembled normal myeloid development (Fig. Data S2B–C). The adherence of AML 
phenotypes to this axis suggests that myeloid developmental programs continue to influence 
the phenotypic diversity of leukemic cells even after malignant transformation. The patterns 
of intratumor heterogeneity support this view, as most patients contained a mixture of 
‘primitive’ and ‘mature’ surface phenotypes (Fig. Data S2D).
Metaclusters highlight inter-patient similarity
Despite the widespread phenotypic diversity observed within patients (Data S2E), the cohort 
landscape revealed a surprising conformity when comparing AML subpopulations across 
different patients. Multiple patients occupied each phenotypic region in the landscape and no 
patient presented a substantially unique phenotype, suggesting that subpopulations could be 
matched across patients, cohort-wide. To examine these cohort-level phenotypes further, we 
pursued a metaclustering approach in which subpopulations from each patient were merged 
by a secondary clustering analysis (Pyne et al., 2009). We represented each AML 
subpopulation by its centroid and used PhenoGraph to group centroids into metaclusters 
(MCs; see Experimental Procedures and Fig. S3A), identifying 14 MCs that delineated the 
major cohort phenotypes (Fig. 3B–C). Each MC had a mixed patient composition, 
containing subpopulations from at least 2 patients and a median of 11 patients.
To evaluate the robustness of these MCs we performed cross-validation and observed high 
reproducibility (see Fig. S3B and Extended Experimental Procedures). Subsequently, we 
used the healthy samples (H1–H5) to interpret the MCs by systematically matching cells 
from healthy bone marrow with the MC surface marker profiles (see Extended Experimental 
Procedures). Several MCs corresponded clearly to non-malignant cell types (constituting a 
small proportion of each leukemic sample), while the remaining MCs represented 
presumptive blast phenotypes. We determined that 7/14 MCs represented malignant 
expansions (MC 1–4, 6, 7, 13), based on the relative frequency of healthy cognates (Fig. 3B) 
and surface marker profiles (Fig. 3C). As expected from the histopathology of AML, the 
blast phenotypes resembled normal primitive and progenitor phenotypes with a myeloid 
bias. Each malignant phenotype was detected in multiple patients, but only MC13 was 
detected in all patients. The CD64+/HLA-DR+ expression profile of MC13 indicates an 
immature monocytic phenotype that was often drastically more abundant in AML than in 
healthy samples. Occupancy in MC13 varied substantially between patients (0.8%–77%), 
consistent with a model of AML as a block in myeloid differentiation with variable severity 
(Tenen, 2003).
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Samples were evaluated quantitatively in terms of their proportional occupancies of the 14 
MCs (Fig. 3D). As expected, the 5 healthy samples were similar to each other and distinct 
from AML. Interestingly, MC occupancies organized the AML samples into subgroups that 
were significantly correlated with other molecular biomarkers (Fig. 3D). For example, 
patients with core binding factor translocation [t(8;21) or inv(16)] had large numbers of cells 
in MC4 and MC13, placing them in a group enriched for this clinical annotation (P = 
0.0014, hypergeometric test). Patients with nucleophosmin mutations displayed a different 
phenotypic distribution—occupancy of MC2, MC7 and MC13—forming another distinct 
patient group (P = 0.0083). Finally, the 3 patients characterized by large occupancies of 
MC1 were all cytogenetically normal (P = 0.018). Taken together, each leukemia, although 
unique, appears to be formed from a limited palette of possible phenotypes. Remarkably, the 
specific composition and relative proportion of MCs was determined in part by genetic 
background, demonstrating a genetic influence on the distribution of phenotypes observed in 
each patient.
Signaling phenotypes define functionally distinct subpopulations
Surface markers have become standard tools for clinical diagnosis and monitoring of blood 
neoplasia (Craig and Foon, 2008). In normal bone marrow, cell surface markers identify 
stem and progenitor cell populations with distinct lineage potential and intracellular 
signaling behaviors (Bendall et al., 2011). However, in AML, no surface marker phenotype 
has been established that consistently distinguishes the more primitive blasts universally 
across patients (Eppert et al., 2011; Taussig et al., 2008; 2010).
We hypothesized that intracellular signaling might be a better surrogate of the underlying 
functional potential and therefore included molecular perturbations known to elicit signaling 
responses that are functionally relevant to normal and malignant hematopoiesis (Table S1). 
Intracellular signaling markers were selected to represent pathways known to be functionally 
and clinically relevant in AML, including JAK/STAT, PI3K/AKT and MAPK. The response 
of each of 14 signaling proteins to each of 16 perturbations revealed a facet of the 
underlying network that controls cellular function, resulting in 224 signaling responses per 
subpopulation. We used these data to build a quantitative signaling phenotype representing 
the structure and function of the intracellular signaling network in each subpopulation.
To fully harness the single-cell nature of our data, we developed SARA (Statistical Analysis 
of Perturbation Response; see Experimental Procedures and Fig. 4A). SARA examines the 
entire single-cell distribution of phosphoprotein intensities to detect meaningful changes 
between two conditions. SARA incorporates a measure of statistical significance through 
permutation testing, producing estimates that are sensitive to small responsive subsets yet 
robust to sampling error and noise. Together, PhenoGraph and SARA distilled high-
dimensional data for 15 million cells into a single matrix of subpopulations and their 
signaling phenotypes (Fig. 4B), revealing a rich variety of signaling potential across 
subpopulations.
Within the healthy samples, surface and signaling phenotypes were tightly coupled, 
consistent with previous reports (Bendall et al., 2011; Gibbs et al., 2011). Hierarchical 
clustering of a curated set of progenitor- and lineage-associated signaling features produced 
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a complete separation of primitive (CD34+) and mature (CD34−) cell types among the 
healthy samples (Fig. 4C–D; P = 2.0×10−52, Student’s t test). In the leukemic samples, the 
same procedure produced a similar stratification of signaling phenotypes, including a set of 
subpopulations that recapitulate the signaling profile of healthy primitive cells. However, 
this stratification of primitive (PS) and mature (MS) signaling had no association with CD34 
expression (P = 0.83, Student’s t test; Fig. 4D). Decoupling of surface and signaling 
phenotypes in the leukemic samples is consistent with evidence that surface markers are 
unreliable proxies of cellular function in AML (Eppert et al., 2011; Gibbs et al., 2011; 
Taussig et al., 2008; 2010). We therefore sought to use signaling phenotypes rather than 
surface phenotypes as alternative proxies for functional state.
Classification of leukemic maturity by signaling phenotype
PhenoGraph and SARA yielded two alternative representations for each subpopulation: a 
16-dimensional surface phenotype, and a 224-dimensional signaling phenotype (Fig. 5A). 
We asked if there was a characteristic signaling phenotype of undifferentiated healthy cells 
that could act as a high-dimensional generalization of the CD34/CD38 surface phenotype, 
which more faithfully captures the functional aspect of the primitive state.
Harnessing the tight coupling between surface and signaling in the healthy system, we 
grounded our analysis in a characterization of healthy subpopulations. PhenoGraph 
metaclustering of the 5 normal marrow samples identified 20 healthy cell types (Fig. 5B and 
Data S3A). Using ANOVA, we examined their signaling profiles for consistent responses 
that were associated with particular cell types and found that a large number of signaling 
responses had significant associations with cell type (Table S2). Many of these were 
induction responses specific to undifferentiated cells, including G-CSF→pSTAT3 (Q = 6.4 
× 10−42) and SCF→pAKT (Q = 1.0 × 10−9), as previously reported (Gibbs et al., 2011).
We then asked whether cell types could be distinguished entirely by their signaling 
phenotypes, rendering surface phenotypes dispensable for characterizing the subpopulations. 
To test this, we developed a framework for classifying subpopulations based on either their 
surface or signaling phenotypes. We derived an extension of PhenoGraph that uses the same 
graph-based model but assigns observations to classes according to user-defined training 
examples (‘PhenoGraph classification’; see Experimental Procedures and Fig. S4A). First, 
we verified that PhenoGraph was capable of recovering “held out” healthy cell type labels 
using a graph derived from surface phenotypes. Performance was evaluated using the cross-
validated correct classification rate (CCR) and indeed, PhenoGraph correctly recovered 
99.42% of the cell type labels in this test. Next, we constructed a graph based only on 
similarity among signaling phenotypes, withholding all surface phenotype information. 
Using this graph, PhenoGraph’s ability to recover the surface-defined labels was modestly 
diminished (CCR = 94%), due to errors distinguishing mature cell types for which 
characteristic signaling phenotypes had not been measured. Focusing on the task of 
distinguishing the most primitive cells (i.e., HSPCs) from the mature cell types, we found 
that signaling phenotypes performed equivalently to surface phenotypes (CCR = 99.85%; 
see Experimental Procedures).
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Considering that signaling phenotypes were sufficient to distinguish healthy primitive cells, 
we hypothesized that the functional state of AML subpopulations could be inferred by direct 
examination of their signaling phenotypes. With the healthy subpopulations as training 
examples, we used PhenoGraph to classify the AML subpopulations, producing an estimate 
of functional state for each subpopulation (e.g., HSPC-like or monocyte-like). Because there 
were two alternative phenotypes for each subpopulation—surface and signaling—we 
performed two separate classifications (Fig. S4B). The result was a data-driven assessment 
of each AML subpopulation, indicating which healthy cell type it resembled in its surface 
marker expression on one hand and in its high-dimensional signaling phenotype on the 
other.
Inferred functional maturity diverges from surface phenotype in AML
The classifiers identified primitive subpopulations within each patient sample, reflecting the 
heterogeneous nature of the samples. At the cohort level, each classifier labeled ~25% of 
subpopulations as primitive, but only 16% were identified as primitive by both classifiers 
simultaneously (Fig. 5C). In many cases (32/99), subpopulations with primitive surface 
marker phenotypes exhibited signaling that resembled mature cells. Conversely, many 
subpopulations displayed primitive signaling in the absence of primitive surface marker 
expression (51/118).
We denote cells labeled primitive by the surface phenotype classifier as Surface-Defined 
Primitive Cells (SDPCs) and cells labeled primitive by the signaling classifier as Inferred 
Functionally Primitive Cell (IFPC). For each patient, the sample proportion assigned to each 
of these labels produced two alternative measures of maturity (%SDPC or %IFPC; Fig. 5D 
and Table S2). This is similar to summarizing the degree of maturation by the enumeration 
of CD34+/CD45low blasts, a practice often used in the clinical diagnosis and classification of 
leukemias (Craig and Foon, 2008). Indeed, we found that %SDPC was highly correlated 
with this standard manual gating procedure (Pearson’s r = 0.96, P = 4.4 × 10−9; Fig. S4C & 
Data S3B). Conversely, %SDPC was only weakly correlated with %IFPC (Pearson’s r = 
0.5; P = 0.05), demonstrating that these two metrics are not redundant in AML. Instead, 
examination of signaling phenotypes in AML often revealed a different degree of maturation 
than was indicated by the surface phenotype. We noted that the degree of discordance 
between IFPC and SDPC assignments was not constant across patients, indicating that the 
tendency of IFPCs to express canonical LSC markers was itself a variable patient feature. 
For example, the IFPCs in patient SJ05 were well represented by the CD34+/CD38mid 
phenotype (Fig. 6, left column). In other cases, IFPCs were found exclusively in the CD34− 
fraction, even when CD34+ blasts were abundant (e.g., SJ16).
Differences in signaling patterns between primitive and mature leukemic subpopulations 
reveal the responses most important for these classifications (Fig. 6; see Fig. S5A for all 
patients). We used canonical variates analysis (see Extended Experimental Procedures for 
details) to quantify this importance, finding that the majority of discriminative power could 
be attributed to 5 responses: G-CSF→pSTAT3, SCF→pAkt, G-CSF→pSTAT5, Flt3-
L→pAkt, and IL-10→pSTAT3 (Fig. S5B and Table S2). Primitive subpopulations displayed 
strong activation in the first four of these responses, which have all been previously 
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implicated in the biology of HSPCs (Gibbs et al., 2011) and in the pathobiology of AML 
(Irish et al., 2004). Additionally, attenuation of the IL-10→pSTAT3 response—a response 
exhibited by mature immune cells—was also a distinctive feature of IFPCs. Other signaling 
responses were strongly associated with primitive subpopulations despite being less 
powerful for classification (Table S2).
Evaluating the ability of surface markers to identify IFPCs, it was clear that no surface 
phenotype could be applied universally across patients (Fig. 6 and Fig. S5A). CD34 was 
often an important label for IFPCs, but in a subset of cases. For example, CD34 marked both 
primitive and mature subpopulations in patient SJ03, where HLA-DR was a more specific 
marker of IFPCs (P = 0.0007 vs. P = 0.003, Student’s t test). In SJ05, where CD34 
expression was tightly associated with IFPCs (P = 7.4 × 10−8), the multiparameter surface 
measurements revealed that CD123 was also an important marker (P = 4.4 × 10−6), whereas 
CD123 did not identify IFPCs in SJ03. Patient SJ11 lacked CD34 expression almost 
entirely, as expected for this nucleophosmin-mutated case (Taussig et al., 2010). In this 
patient, IFPCs were distinctly labeled by elevated expression of CD47 (P = 7.1 × 10−6) and 
CD123 (P = 3.4 × 10−5). Surprisingly, we found that CD34 expression can be strongly anti-
correlated with primitive signaling, as in patient SJ16, where CD34 expression was higher in 
mature cells (P = 0.0027) and IFPCs were marked instead by elevated expression of CD117 
(P = 0.0026). Complete median surface marker profiles for IFPC and non-IFPC 
subpopulations are displayed in heat maps for each patient in Figs. 6 and S5A.
Primitive signaling phenotype identifies clinically prognostic gene expression signature
Ultimately, the importance of intratumor heterogeneity depends on whether functionally 
distinct subpopulations influence clinical outcomes, especially patient survival (Pearce et al., 
2006). While our cohort was too small for survival analysis, genome-wide expression arrays 
for 15 of our 16 patients were available from a previous study (Radtke et al., 2009), 
providing a link to larger cohorts for which gene expression and survival data were 
available. Because our samples displayed a wide range of IFPC frequencies (Fig. 5D), we 
reasoned that this variance could be exploited to identify genes whose expression covaried 
with these frequencies by in silico expression deconvolution (Lu et al., 2003). As IFPC 
frequency varies across samples, genes expressed specifically by these cells should be 
detectably more or less abundant in the bulk gene expression measurements, thereby 
providing an estimate of %IFPC in independent samples from the level of this gene 
signature, measured in bulk.
We developed a deconvolution method based on linear regression and cross-validation and 
used both %IFPC and %SDPC to produce two gene expression signatures, containing 42 
and 49 genes, respectively (see Experimental Procedures, Fig. 7A and Table S3). To 
characterize these signatures, we queried the Molecular Signatures Database (Subramanian 
et al., 2005) for significant annotations overlapping with each. The SDPC signature—which 
contained CD34 among its top-ranked genes—was highly enriched for gene sets associated 
specifically with CD34+ AML (Table S3). Alternatively, the most significant annotation for 
the IFPC signature was a set of genes upregulated in CD133+ hematopoietic stem cells 
(Jaatinen et al., 2006) (Q = 5.5 × 10−8; Table S3). CD133 marks healthy stem cells that are 
Levine et al. Page 10













possibly more primitive than CD34+ HSCs (Gallacher et al., 2000) and has been linked to 
cancer stem cells in multiple cancer types (Collins et al., 2005; O’Brien et al., 2007). The 
mean expression of each signature was highly correlated with its corresponding 
subpopulation frequency (Fig. S6A), indicating that the signature mean was an appropriate 
proxy for these frequencies in independent cohorts.
We tested our signatures in two independent cohorts of adult AML for which both gene 
expression and survival data were available (Metzeler et al., 2008). While the SDPC 
signature was associated with survival in one cohort, this was not replicated in the other 
(Fig. S6B). Alternatively, the IFPC signature was predictive of poor survival in both cohorts 
(Fig. 7B). Combining the data into a single, large cohort (n = 242), the IFPC signature was 
highly predictive of poor survival (P = 4.8 × 10−6, Hazard Ratio [HR] = 3.4), while the 
SDPC signature formed a less significant predictor (P = 0.005, HR = 1.6). To test these 
signatures against each other, we placed them together in a bivariate Cox regression model. 
In this setting, the IFPC signature retained its predictive power (P = 8.2 × 10−5, HR = 3.0), 
while the SDPC signature became completely uninformative for survival (P = 0.29, HR = 
1.2).
We examined the relationship between the IFPC signature and three signatures reported by 
(Eppert et al., 2011), which were also developed to capture primitive gene expression 
programs in AML. For each Eppert signature, we were able to reproduce the significant 
correlation with survival in the data from (Metzeler et al., 2008). To assess the prognostic 
value of the IFPC signature when these other signatures were known, we tested three 
bivariate Cox regression models in which each of the Eppert signatures was used as a 
predictor alongside the IFPC signature (see Extended Experimental Procedures). The IFPC 
signature proved to be a stronger predictor of survival than any of the Eppert signatures 
(Table S3). In each model, the IFPC signature retained significance (P < 0.005), while each 
Eppert signature became statistically insignificant (P > 0.07). In a multivariate Cox 
regression model containing all signatures (IFPC, SDPC and the Eppert signatures), only the 
IFPC signature retained significance (P = 0.012, HR = 2.4; Table S3).
DISCUSSION
Tissues are complex populations of cells residing in phenotypically and functionally diverse 
states. A key challenge is to dissect the high-dimensional structure of these complex 
populations into components that can be studied individually and collectively. In AML, 
where the relationship between phenotypic and functional heterogeneity has been elusive, 
we used mass cytometry to profile both surface and signaling features simultaneously in 
millions of leukemic cells.
PhenoGraph revealed a phenotypic landscape of a pediatric AML cohort, providing a 
comprehensive overview of the major phenotypes and an explicit characterization of intra- 
and intertumor heterogeneity. The landscape resembled normal myeloid development, but 
with aberrations resulting from malignant accumulation of cells and neoplastic divergence 
from normal phenotypes. However, this AML landscape was surprisingly restricted to a 
limited repertoire of 14 MCs, each defined by distinct surface marker patterns. Importantly, 
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these MCs were shared among a wide variety of AML genetic subtypes, yet genetics had a 
detectable influence on the phenotypic composition of each patient. Together these 
observations suggest the persistence of developmental mechanisms that control the available 
repertoire of phenotypes even in the context of genetic dysregulation associated with cancer.
We used mass cytometry in conjunction with molecular interrogation to construct signaling 
phenotypes that reflect differences in functional potential between subpopulations. Surface 
and signaling phenotypes displayed tight coregulation in healthy samples, whereas this 
coregulation was broken in AML. This substantial decoupling of surface and signaling 
phenotypes in the leukemic cells renders the surface markers typically used in diagnostics 
unreliable proxies of cellular state and function in AML.
Our demonstration that surface markers are unreliable reporters of signaling state in AML 
sheds light on the controversies surrounding the LSC model, which rely on manual gating 
and surface marker expression to define subpopulations. To avoid the assumption that 
surface markers indicate the functional state of leukemic cells, we used healthy HSPCs to 
define a primitive signaling phenotype, reflecting the functional state of undifferentiated 
hematopoietic cells. We found that the primitive signaling phenotype was present in most 
AML samples and could be used to identify intratumor functional heterogeneity. Leukemic 
cells displaying primitive signaling (Inferred Functionally Primitive Cells [IFPCs]), were 
thereby identified using datadriven techniques and without reference to surface phenotypes.
The IFPC phenotype was found to occur in most AML samples at varying frequencies and 
with variable surface phenotypes, often with low or absent CD34 expression. While no 
universal surface phenotype captured IFPCs across patients, within each patient IFPCs 
displayed homogeneous expression in certain markers—markers whose importance was 
neither universal nor unique. Our results suggest that a subset of leukemic cells maintains a 
conserved, progenitor-like signaling program that phenocopies the regulatory state of normal 
HSPCs, regardless of surface marker expression and underlying genetic mutations.
Deconvolution analysis of microarray data identified a gene expression signature associated 
with the IFPC phenotype that can serve as a proxy for the frequency of this phenotype in a 
given sample. This gene expression signature was enriched for annotations related to 
primitive hematopoietic cells and included genes—such as PROM1, SOCS2, and CD96—
that have been previously associated with healthy and/or leukemic stem cells (Toren et al., 
2005). Importantly, this gene expression signature predicted survival in multiple 
independent AML patient cohorts, suggesting that this signaling-based definition describes a 
clinically relevant cellular phenotype.
It was previously demonstrated (Eppert et al., 2011) that functional characterization by 
physical sorting and xenotransplantation could be used to identify genes correlated with 
patient survival. Our analysis is conceptually related, but instead of differential expression 
between sorted cells, we used in silico deconvolution to identify genes, based on the 
measured cellular frequencies of the IFPC phenotype. Ultimately, both approaches seek to 
identify primitive cells by means that emphasize functional over surface phenotypes, and to 
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test whether the predominance of primitive cells—approximated by expression of a gene 
signature—is associated with poor survival.
Our findings were enabled by computational dissection of intratumor heterogeneity. 
PhenoGraph creates a graph-based model of cellular phenotypes, similar to that used 
previously to identify developmental trajectories (Bendall et al., 2014) and in this case 
defining phenotypes as communities of densely interconnected nodes. PhenoGraph is 
general and highly scalable both in terms of dimensionality and sample size, making it 
suitable in a wide range of settings for which single-cell population structure is of interest, 
including other cancers or healthy tissues, and for use with other emerging single-cell 
technologies such as single-cell RNAseq. Many such cases are presented by the tumor 
microenvironment, including drug-resistant tumor subpopulations, infiltrating immune cells, 
and reactive stromal components. These methods are also applicable to healthy tissues, 
within which a large diversity of cell types remains uncharted.
Our signaling-based definition of primitive cells warrants further investigation as it may 
indicate pathways that influence the maturation of leukemic cells and could be leveraged 
therapeutically to block survival or direct differentiation. More broadly, this molecular 
interrogation approach could be used to characterize primitive cells in any cancer where a 
cognate healthy primitive cell type is available to serve as a reference point. This study 
provides a framework for interrogating and discovering other features of cell biology that 
define network response states and their associated mechanistic or clinical outcomes.
EXPERIMENTAL PROCEDURES
Patient samples
Sixteen (16) cryopreserved diagnostic bone marrow mononuclear cells (BMMC) of pediatric 
AML patients were supplied by St. Jude Children’s Hospital (Memphis, TN) (Table S1). For 
healthy adult controls, cryopreserved healthy BMMCs were purchased from AllCells, Inc. 
(Emeryville, CA). All human samples were obtained with informed consent in compliance 
with IRB-approved protocols.
Mass Cytometry Analysis
Mass cytometry analysis including data pre-processing is as previously described (Bendall et 
al., 2011; Finck et al., 2013; Zunder et al., 2015). Surface marker expression was normalized 
based on the maximum intensity observed in healthy samples, determined as the 99.5th 
percentile of the ~3M healthy bone marrow cells. Data from all samples were divided by 
these maximum values, yielding expression values that can be interpreted as x-fold of the 
maximum observed in healthy. Mass cytometry data are publicly available at http://
cytobank.org/nolanlab/reports. See Extended Experimental Procedures for full details.
Microarray data and normalization
Matched Affymetrix U133A gene expression arrays for the 16 pediatric AML patients 
(Radtke et al., 2009) were downloaded from the Gene Expression Omnibus (GSE14471). 
Gene expression and survival data for 242 cytogenetically normal adult AML patients from 
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two independent cohorts (Metzeler et al., 2008) were downloaded from the Gene Expression 
Omnibus (GSE12417). All microarray data were processed and normalized as described 
previously (Akavia et al., 2010).
The PhenoGraph algorithm
PhenoGraph takes as input a matrix of N single-cell measurements and partitions them into 
subpopulations by clustering a graph that represents their phenotypic similarity. PhenoGraph 
builds this graph in two steps. First, it finds the k nearest neighbors for each cell (using 
Euclidean distance), resulting in N sets of k-neighborhoods. Second, it operates on these sets 
to build a weighted graph such that the weight between nodes scales with the number of 
neighbors they share. The Louvain community detection method (Blondel et al., 2008) is 
then used to find a partition of the graph that maximizes modularity. See Extended 
Experimental Procedures for full details on the method and an assessment of its accuracy, 
efficiency, and robustness compared to other methods. Source code for PhenoGraph is 
available online for MATLAB and Python (www.c2b2.columbia.edu/danapeerlab/html/
software.html).
PhenoGraph classification
Given a dataset of N d-dimensional vectors, M distinct classes and a vector providing the 
class labels for the first L samples, the PhenoGraph classifier assigns labels to the remaining 
N–L unlabeled vectors. First, a graph is constructed as described above. The classification 
problem then corresponds to the probability that a random walk originating at unlabeled 
node x will first reach a labeled node from each of the M classes. This defines an M-
dimensional probability distribution for each node x that records its affinity for each class. 
See Extended Experimental Procedures for full details on this method, as well as an 
evaluation of its performance on benchmark data.
Applying PhenoGraph and SARA to AML cohort
We ran PhenoGraph on each sample individually, defining subpopulations based on 
expression of the 16 surface markers. For each sample, all ex vivo conditions were pooled as 
we previously demonstrated that surface marker distributions are not altered by these short-
term perturbations (Bendall et al., 2011). PhenoGraph was run on the normalized surface 
phenotype matrices for each sample, with the parameter k=50.
Subpopulation signaling phenotypes were computed for each cluster using SARA, followed 
by z-score standardization. See Extended Experimental Procedures for full details.
Defining AML metaclusters
Each AML subpopulation was represented by its centroid, resulting in a 425 × 16 matrix. 
PhenoGraph was run on 425 subpopulations centroids with the parameter k=15, resulting in 
14 metaclusters (MCs) delineating the major cohort phenotypes. These MCs are a robust 
feature of the data and remained consistent when the metaclustering was performed on 
subsets of patients (see Extended Experimental Protocols and Fig. S3B). To characterize 
these MCs, we systematically matched cells from healthy bone marrow (H1–H5) with the 
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MC surface marker profiles using linear discriminant analysis. See Extended Experimental 
Procedures for full details.
PhenoGraph classification of leukemic subpopulations
We used the PhenoGraph classifier to classify leukemic subpopulations based on training 
examples provided by the healthy subpopulations. For each, k-neighbor graphs (k = 15) were 
constructed over 616 subpopulations (healthy and leukemic) using similarities derived either 
from surface or signaling phenotypes. Specifically, we used a weighted Euclidean distance 
in which each phenotypic feature was weighted according to its statistical association with 
known cell types in the healthy samples. Each AML subpopulation was classified based on 
its phenotypic proximity to the healthy training examples. Classification was performed 
using surface and signaling classifiers separately, resulting in two alternative classifications 
per AML subpopulation (Figs. 6 and S4B). See Extended Experimental Procedures for full 
details.
Gene expression signatures and survival analysis
For each score, %SDPC or %IFPC, a set of associated genes was defined based on 
correlation with the expression patterns across patients, using linear regression. This in silico 
gene expression deconvolution (Lu et al., 2003), assumes that changes in bulk expression of 
certain genes will track with changes in subpopulation size. We used leave-two-out cross-
validation across 15 patients to select genes that placed in the top one percentile and had a 
standard deviation across subsets < 5%.
We used gene expression and survival data for 242 cytogenetically normal adult AML 
patients from two independent cohorts (Metzeler et al., 2008). For each patient, the 
frequency of a cell type (%IFPC or %SDPC) was estimated as the mean expression intensity 
of the associated gene signature. For Kaplan-Meier analysis, patients were stratified into two 
groups based on the median expression value of the signature of interest. See Extended 
Experimental Procedures.
Supplementary Material
Refer to Web version on PubMed Central for supplementary material.
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Fig. 1. Mass cytometry analysis of signaling responses in pediatric acute myeloid leukemia
(A) Summary of experimental design. (B) PhenoGraph method for clustering high-
dimensional single-cell data. Each node in the neighbor graph represents one of 500 random 
cells from healthy donor H1 colored by CD34 expression. CD34+ HSPCs form a dense 
subgraph and are automatically assigned to a single subpopulation. See Figure S1 and 
Experimental Procedures for more details on the PhenoGraph algorithm. (C) HSPCs 
identified by PhenoGraph from donor H1. This subpopulation (red histograms) had a 
CD34+/CD45low phenotype relative to the other cells in the sample (gray histograms). Each 
Levine et al. Page 18













PhenoGraph subpopulation contained cells from all perturbations, permitting analysis of 224 
signaling responses.
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Fig. 2. PhenoGraph clustering recapitulates manual assignments of healthy immune cells
(A) viSNE (Amir et al., 2013) display of 30,000 cells from healthy BPMC benchmark data 
(Bendall et al., 2011). Cells are colored by cell type assignments established by manual 
gating (left panel) or subpopulations detected by PhenoGraph (right panel). (B) Comparison 
PhenoGraph to other methods on the benchmark data set, assessed for ability to recover the 
manual cell type assignments shown in (A, left panel), quantified using the F-measure 
statistic (Aghaeepour et al., 2013) and normalized mutual information (Fig. S2C). Box plots 
show the distributions of F-measure computed from 50 random samples of 20,000 cells 
from the full data set. PhenoGraph was tested with 4 different settings of its single parameter 
k, small interquartile ranges demonstrate that PhenoGraph accurately identifies the structure 
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of the original population and is robust to random subsampling and its single parameter k. 
Comparison on additional benchmark datasets is provided in Data S1G–I.
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Fig. 3. Intra- and intertumor heterogeneity is visible across the phenotypic landscape of pediatric 
AML
(A) t-SNE landscape of average surface marker expression of non-lymphoid PhenoGraph 
clusters from the AML cohort. Each cluster is represented by a single point scaled to 
represent its sample proportion and in the main panel colored by patient identity. Normal 
bone marrow cell types (H1–H5; blue) provide landmarks for interpreting the phenotypes of 
the leukemic bone marrow samples (SJ01–SJ16). In additional panels each subpopulation is 
colored by median expression of indicated surface markers. (B) PhenoGraph applied to 
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cluster centroids consolidated the 616 patient-level subpopulations into 14 cohort-level 
metaclusters (MCs). Stacked columns indicate the contribution made by each patient to each 
MC. (C) Average surface marker expression in each MC, summarizing the major 
phenotypes observed across the cohort. Columns match those represented in B. (D) 
Intrapatient heterogeneity for each patient is represented graphically by a horizontal bar in 
which segment lengths represent the proportion of the patient assigned to each MC, colored 
according to the accompanying legend (bottom right). Hierarchical clustering of these 
patient descriptions revealed that some patterns of intrapatient heterogeneity were 
significantly correlated with genetic biomarkers. (CBF, core binding transcription factor 
translocation: P=0.0014; NPM1: P=0.0083, nucleophosmin mutation; CN, cytogenetically 
normal: P=0.018).
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Fig. 4. Analysis of perturbation response generates signaling phenotypes
(A) A cartoon depicting how SARA uses the single-cell distributions together with 
permutation testing to score signaling response. (B) SARA, applied to every signaling 
molecule for every perturbation in every subpopulation, produced ~138,000 responses, 
which were compiled into 224-dimensional signaling phenotypes for each subpopulation 
(columns) for each of 616 subpopulations (rows). Rows and columns ordered by 
agglomerative linkage. (C) Hierarchical clustering of 4 developmentally-relevant signaling 
responses in the healthy samples (top panel) identified patterns of primitive signaling (PS) 
Levine et al. Page 24













and mature signaling (MS) correlated with expression of CD34 and CD45, in the healthy 
samples. Hierarchical clustering of the same signaling responses in the AML samples 
(bottom panel) identified a cluster of subpopulations that recapitulated the primitive 
signaling pattern, but lacked a consistent surface phenotype. Color scales are as in Figures 
3A and 4A. (D) Box plots comparing CD34 expression between signaling clusters identified 
in (C). CD34 expression was significantly associated with primitive signaling only in the 
healthy samples.
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Fig. 5. Data-driven scoring of leukemic maturity by either surface or signaling phenotype
(A) Each PhenoGraph subpopulation has two alternative phenotypes: surface and signaling 
(B) Normal cell types identified in healthy samples display characteristic surface and 
signaling phenotypes, represented by heat maps. Each row represents the indicated cell type. 
Surface markers (left) and signaling responses (right) are colored as in (A). Signaling 
responses are ordered from left to right by decreasing significance of association with cell 
type (Table S2). (C) The same t-SNE map presented in Fig. 3A, labeled by results of 
PhenoGraph classification. Colors depict whether a subpopulation was assigned to either, 
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both, or neither primitive class as determined IFPC or SDPC; (see Fig. S4A–B). (D) 
Frequencies of primitive cells: %IFPC or %SDPC for each patient sample.
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Fig. 6. Leukemic subpopulations with primitive signaling exhibit diverse surface phenotypes
Detailed surface and signaling phenotypes of IFPC subpopulations in 4 representative 
samples. Each row represents a particular patient using a number of visuals. Biaxial dot 
plots (left) show the CD34/CD38 phenotype of IFPCs (red) in each sample. IFPCs displayed 
the canonical primitive CD34+/CD38mid phenotype in only a subset of samples. The IFPCs 
displayed using the t-SNE landscape of Fig. 3A (center; IFPCs in green, non-IFPCs in 
maroon, healthy cells in gray). Heat maps (right) display the signaling and surface 
phenotypes of all non-lymphoid subpopulations of each sample, stratified by IFPC 
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classification (indicated by green and maroon bars). Signaling responses are ordered as in 
Fig. 5B. Signaling responses marked in bold with vertical lines were especially distinctive of 
IFPCs (see Main Text and Extended Experimental Procedures). See Figure S5A for all 
patients not shown here.
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Fig. 7. Frequency of IFPCs identifies a gene expression signature that predicts clinical outcome
(A) IFPC gene signature identified by deconvolution of bulk expression data using IFPC 
frequency. The heat map displays expression of each gene in the bulk measurements. Rows 
are alphabetically ordered; columns are ordered by the mean expression of the genes in the 
signature. (B) The mean of the IFPC signature forms a clinically significant prognostic 
indicator of overall survival in 2 independent cohorts of adult AML (Metzeler et al., 2008). 
Patients were assigned to groups for Kaplan-Meier analysis based on whether their IFPC 
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expression score was below or above the cohort median. P values obtained from log-rank 
test.
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